Thiazolidinediones Linked to Risk for Osteoporotic Fracture

Εκτυπώστε το άρθρο Email This Post
Post2PDF

Thiazolidinediones (TZDs), which are used to treat type 2 diabetes mellitus, are associated with a 1.3-fold elevation in risk for osteoporotic fracture compared with other antidiabetic medications, according to a report published online March 6 in Pharmacoepidemiology and Drug Safety.

Read the full article from here:

http://www.medscape.com/viewarticle/759885?sssdmh=dm1.765109&src=nldne

 

  • This study was supported by a grant from the European Calcified Tissue Society and by the Dutch Organisation of Scientific Research. The Department of Pharmacoepidemiology and Clinical Pharmacology, which employs Dr. Bazelier and 3 coauthors, has received unrestricted funding for pharmacoepidemiologic research from GlaxoSmithKline, Novo Nordisk, the private–public-funded Top Institute Pharma, the Dutch Medicines Evaluation Board and the Dutch Ministry of Health. Two coauthors also work for the General Practice Research Database in the United Kingdom.
  • Pharmacoepidemiol Drug Saf. Published online March 6, 2012.
    Share
    source:www.medscape.com, medical news, author:Ricki Lewis, PhD
    Εκτυπώστε το άρθρο Email This Post Post2PDF

    web design

    WebOlution